|Mr. David Dally (CEO)
Mr. David Dally was appointed CEO in November 2013. Previously he was CFO; having joined MerLion in March 2007.
David qualified as a chartered accountant with Ernst and Young. He joined Amersham plc in 1991 and held a number finance roles including Manager of Strategic Planning and VP Finance North America, managing the merger of Amersham Life Science with Pharmacia Biotech. Since 2002 David has held CFO positions at KuDOS Pharmaceuticals Ltd, an early-stage drug discovery and development in Cambridge, UK, which was sold to Astra Zeneca for $210m, and subsequently at Rhytec Ltd, a medical devices company.
|Dr. Andreas Vente (Managing Director MerLion Pharmaceuticals GmbH)
Dr. Andreas Vente joined MerLion in 2006 in conjunction with the acquisition of Combinature Biopharm AG. Before becoming Managing Director of MerLion’s drug development subsidiary in Berlin in 2009, he was head of project management and non-clinical development. For Combinature Biopharm AG he worked as COO and in various management positions. Between 1998 and 2000 he was the Head of the Laboratories of the RZPD German Resource Center for Genome Research GmbH. Earlier, he worked as a postdoctoral fellow at the ETH, Zürich and the German Cancer Research Center, Heidelberg. Dr. Vente obtained an MSc in Biology from the University of Cologne, Germany, in 1992 and a PhD at the Max Planck Institute for Plant Breeding Research, Cologne, in 1996.